EXHIBIT 99.1 Financial Results Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT "We continue to make strong progress with our two key priorities for the year – advancing soquelitinib for PTCL and generating early data for soquelitinib for atopic dermatitis," said Richard A. Miller, M.D., cofounder, president and chief executive officer of Corvus. "We are encouraged that two newly evaluabl ...

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to t ...

Corvus Pharmaceuticals (CRVS) has been on a downward spiral lately with significant selling pressure. After declining 25% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...

Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company's selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the initiation of the Company's randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in pa ...

Corvus Pharmaceuticals (CRVS) has been on a downward spiral lately with significant selling pressure. After declining 18.4% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.How to Determine if a Stock is OversoldWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting wh ...

Corvus Pharmaceuticals (CRVS) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the syste ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Leiv Lea - CFO Richard Miller - CEO Jeff Arcara - CBO Conference Call Participants Jeff Jones - Oppenheimer Liang Cheng - Jefferies Rosemary Li - Cantor Fitzgerald Operator Good afternoon everyone. Thank you for standing by and welcome to the Corvus Pharmaceuticals' Fourth Quarter and Full Year 2023 Business Update and Financial Results Conference Call. At th ...

Table of Contents (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 001-37719 46-4670809 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number) Securities registered pursuant to Section 12(g) of the Act: None DOCUMENTS INCORPORATED BY REFERENCE Table of Contents ...

EXHIBIT 99.1 Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib's potential to address the need for new treatments for PTCL Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURL ...

Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib's potential to address the need for new treatments for PTCL   Conference call today at 4:30 p.m. ET / 1:30 p.m. PT BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOB ...